These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 16134271)
41. Good enough to use for research, but not good enough to benefit from the results of that research: are the clinical HIV vaccine trials in Africa unjust? Yearby R De Paul Law Rev; 2004; 53(3):1127-54. PubMed ID: 16200692 [No Abstract] [Full Text] [Related]
42. The pharmaceutical industry's responsibility for protecting human subjects of clinical trials in developing nations. Kelleher F Columbia J Law Soc Probl; 2004; 38(1):67-106. PubMed ID: 16755695 [TBL] [Abstract][Full Text] [Related]
43. AIDS activists fail to block 'reasonable pricing' reform. Gavaghan H Nature; 1995 Jan; 373(6512):272. PubMed ID: 7830751 [No Abstract] [Full Text] [Related]
44. eJIAS and the Bristol-Myers Squibb Foundation's Secure the Future Program. Damonti J MedGenMed; 2004 Jul; 6(3):57. PubMed ID: 15520681 [No Abstract] [Full Text] [Related]
45. Double standards and benefit-sharing: a response to Linda Barclay. chroeder D Monash Bioeth Rev; 2008 Oct; 27(4):45-51. PubMed ID: 19760854 [No Abstract] [Full Text] [Related]
46. Millennium bugs. AIDS in Africa threatens the United States. It should not act accordingly. Nature; 2000 Jan; 403(6766):117. PubMed ID: 10671142 [No Abstract] [Full Text] [Related]
47. AIDS and the politics of drug lag. Vogel D Public Interest; 1989; (96):73-85. PubMed ID: 10294053 [No Abstract] [Full Text] [Related]
48. 2 paths of Bayer drug in 80's: riskier one steered overseas. Bogdanich W; Koli E N Y Times Web; 2003 May; ():A1, C5. PubMed ID: 12812170 [No Abstract] [Full Text] [Related]
49. The role of the pharmaceutical industry in disseminating pharmacovigilance practice in developing countries. Shani S; Yahalom Z Food Drug Law J; 2008; 63(3):701-11. PubMed ID: 19031669 [No Abstract] [Full Text] [Related]
50. AIDS drugs in research. Hosp Pharm; 1990 Jun; 25(6):572-3, 576. PubMed ID: 10104831 [No Abstract] [Full Text] [Related]
51. Pharma + profits = continued aids epidemic. Verma IM Mol Ther; 2001 Apr; 3(4):419. PubMed ID: 11319899 [No Abstract] [Full Text] [Related]
52. Addressing vulnerabilities in developing countries. Kasturiaratchi ND Dev World Bioeth; 2001 Nov; 1(2):148-52. PubMed ID: 12872757 [No Abstract] [Full Text] [Related]
53. Therapy for AIDS: affordable and accessible. Kalantri SP Natl Med J India; 2004; 17(3):179. PubMed ID: 15253413 [No Abstract] [Full Text] [Related]
54. Vulnerability, scientific research and AIDS. Diniz D Dev World Bioeth; 2001 Nov; 1(2):153-5. PubMed ID: 12872758 [No Abstract] [Full Text] [Related]
55. A new vision for clinical trials in Africa. The PLoS Med; 2004 Dec; 1(3):e71. PubMed ID: 15630472 [TBL] [Abstract][Full Text] [Related]
56. IRBs: going too far or not far enough? Felten DL Science; 2006 Sep; 313(5792):1388-9; author reply 1388-9. PubMed ID: 16959990 [No Abstract] [Full Text] [Related]
57. PMA survey cites advances in AIDS research. Am Pharm; 1993 Apr; NS33(4):8-9. PubMed ID: 8475858 [No Abstract] [Full Text] [Related]
58. [The role of politics in the successful fight against AIDS in Uganda]. Anders J Lakartidningen; 2006 May 17-30; 103(20):1629. PubMed ID: 16800091 [No Abstract] [Full Text] [Related]
59. Section on AIDS: the politics of survival. Introduction. Krieger N; Margo G Int J Health Serv; 1990; 20(4):583-8. PubMed ID: 2265876 [TBL] [Abstract][Full Text] [Related]
60. Medical morals: an exchange. Bloom BR New York Rev Books; 2001 Mar; 48(4):E1-E3; author reply E3-E5. PubMed ID: 17175596 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]